EUVIMEDEUVIMED entdecken
Crossref

Structure Optimization of c-Jun N-terminal Kinase 1 Inhibitors for Treating Idiopathic Pulmonary Fibrosis

Yi Huang, Fengling Liu, Shuhua Ren, Yuanqing Ding, Man Chi, Weiwei Huang, Wenjing Gu, Hewen Qian, Yaxia Yuan iD, Shurong Hou, Xiabin Chen, Lei Ma iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yi Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, C…. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Protein Kinase Inhibitors, Mitogen-Activated Protein Kinase 8. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal lung disease with an elusive etiology. Aberrant activation of c-Jun N-terminal kinase 1 (JNK1) has been implicated in its pathogenesis. Through a combination of structure-based drug design and structure-activity relationship (SAR) optimization, a series of pyrimidine-2,4-diamine scaffold derivatives have been developed as potent JNK1 inhibitors. Compound E1 was identified with low nanomolar JNK1 inhibitory potency (IC50 = 2.7 nM). The introduction of a dimethylamine side chain has significantly enhanced the ability of E1 to inhibit c-Jun phosphorylation, surpassing the clinical candidate CC-90001. Molecular dynamics simulations revealed a binding free energy of -50.46 kcal/mol for E1. Moreover, E1 displayed satisfactory pharmacokinetic properties, with a bioavailability of 69% in rats. Furthermore, compound E1 exerted significant antifibrotic effects in a bleomycin-induced IPF mouse model and prevented a TGF-β-induced epithelial-to-mesenchymal transition in vitro. These findings position E1 as a promising lead for further drug development targeting IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisProtein Kinase InhibitorsMitogen-Activated Protein Kinase 8AnimalsStructure-Activity RelationshipHumansMiceRatsBleomycinMaleRats, Sprague-DawleyMolecular Dynamics SimulationPyrimidinesEpithelial-Mesenchymal TransitionMice, Inbred C57BLDrug DesignMolecular Structure

Substanzen

Protein Kinase InhibitorsMitogen-Activated Protein Kinase 8BleomycinPyrimidines

Autor:innen und Institutionen

  • Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
  • School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
  • Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, and Collaborative Innovation Center of Traditional Chinese Medicines…
  • Hangzhou Matrix Biopharmaceutical Co., Ltd, Hangzhou, Zhejiang 311121, China.
  • Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, United States.

ORCID-Profile: Yaxia Yuan, Lei Ma

Förderung

  • National Natural Science Foundation of China
  • Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism

Zitieren

APA

Huang, Y., Liu, F., Ren, S., Ding, Y., Chi, M., Huang, W., Gu, W., Qian, H., Yuan, Y., Hou, S., Chen, X., & Ma, L. (2024). Structure Optimization of c-Jun N-terminal Kinase 1 Inhibitors for Treating Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01764

Vancouver

Huang Y, Liu F, Ren S, Ding Y, Chi M, Huang W, et al. Structure Optimization of c-Jun N-terminal Kinase 1 Inhibitors for Treating Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01764

BibTeX
@article{Huang2024,
  author = {Huang, Yi and Liu, Fengling and Ren, Shuhua and Ding, Yuanqing and Chi, Man and Huang, Weiwei and Gu, Wenjing and Qian, Hewen and Yuan, Yaxia and Hou, Shurong and Chen, Xiabin and Ma, Lei},
  title = {Structure Optimization of c-Jun N-terminal Kinase 1 Inhibitors for Treating Idiopathic Pulmonary Fibrosis},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01764}
}
Kostenlos starten →